OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Rating of “Moderate Buy” by Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has received an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $13.4286.

OPRX has been the subject of a number of analyst reports. UBS Group set a $10.00 price target on OptimizeRx in a research report on Wednesday, May 13th. Wall Street Zen downgraded OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. B. Riley Financial cut their price target on OptimizeRx from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Stephens reduced their price objective on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 13th. Finally, Stifel Nicolaus lowered their price objective on shares of OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th.

OptimizeRx Trading Up 0.3%

Shares of OPRX traded up $0.02 on Tuesday, hitting $6.37. 103,301 shares of the stock traded hands, compared to its average volume of 459,931. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $119.50 million, a P/E ratio of 18.20 and a beta of 1.08. The stock’s 50 day moving average is $5.45 and its two-hundred day moving average is $7.92. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $22.25.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Tuesday, May 12th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The firm had revenue of $19.84 million during the quarter, compared to analysts’ expectations of $18.74 million. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. As a group, sell-side analysts predict that OptimizeRx will post 0.51 earnings per share for the current year.

Institutional Trading of OptimizeRx

Several institutional investors have recently made changes to their positions in the business. Quantbot Technologies LP bought a new position in OptimizeRx in the 2nd quarter valued at approximately $44,000. BNP Paribas Financial Markets boosted its holdings in shares of OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after purchasing an additional 2,215 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in shares of OptimizeRx in the fourth quarter worth approximately $62,000. Aaron Wealth Advisors LLC purchased a new position in shares of OptimizeRx during the first quarter valued at approximately $66,000. Finally, Worth Venture Partners LLC purchased a new position in shares of OptimizeRx during the third quarter valued at approximately $220,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.